teplizumab   Click here for help

GtoPdb Ligand ID: 12252

Synonyms: humanized OKT3 | MGA031 | PRV-031 | teplizumab-mzwv | Tzield®
Approved drug Immunopharmacology Ligand
teplizumab is an approved drug (FDA (2022))
Compound class: Antibody
Comment: Teplizumab is a humanized anti-CD3e monoclonal antibody that was originally developed as an immunomodulatory agent. Structurally it is a modified version of the mouse antibody muromonab-CD3 (mOKT3) that has been used to reverse steroid-resistant renal allograft rejection. Alterations in the OKT3 CH2 domain disrupt Fcγ receptor binding, and blocks antibody-mediated effector cells functions and cytokine release [5,7]. It was advanced to extended clinical evaluations for potential to protect pancreatic β-cells in newly diagnosed type 1 diabetes (T1D) patients [4,6], following evidence that it impaired expansion of alloreactive anti-β cell T cells [5], and that a single short course of teplizumab treatment could induce a long-lasting improvement in patients' C-peptide responses and clinical parameters (including preservation of insulin production) in the early stages of T1D [2-3].
Classification Click here for help
Compound class Antibody
Approved drug? Yes. FDA (2022)
International Nonproprietary Names Click here for help
INN number INN
8869 teplizumab
Synonyms Click here for help
humanized OKT3 | MGA031 | PRV-031 | teplizumab-mzwv | Tzield®
Database Links Click here for help
Specialist databases
IMGT/mAb-DB 92
Other databases
GtoPdb PubChem SID 473153840
Search PubMed clinical trials teplizumab
Search PubMed titles teplizumab
Search PubMed titles/abstracts teplizumab